Circulating tumor DNA (ctDNA) can be detected in plasma samples sometimes several years prior to a clinical diagnosis of cancer, according to research ...

Posttreatment ctDNA positivity correlates with worse relapse-free survival and earlier recurrence in patients with locally advanced cervical cancer, real-world data show.

Liquid biopsy ctDNA reveals targets and flags residual disease in esophageal and gastric cancers, hinting at earlier relapse ...

Hayley Knollman, MD, explains how ctDNA and genomic testing impact ER-positive metastatic breast cancer care, guiding ...

Minimal residual disease (MRD) continues to be a central focus at the AACR meeting. The small numbers of cancer cells that ...

HaystackMRD, made by Haystack Oncology within Quest Diagnostics, looks for signs of cancer that conventional methods may miss ...

For many families, eight years of uncertainty meant repeated specialist visits, inconclusive genetic tests and the growing ...